M Pharmaceuticals, MQ on CSE

Discussion in 'Canadian Stocks Message Boards' started by Million$man, Sep 22, 2016.

Tags:
  1. Million$man

    Million$man New Member

    Joined:
    Jul 26, 2016
    Messages:
    23
    Likes Received:
    0
    Guys and Gals, check out MQ.

    $$$ Quick Summary $$$
    They took the best ever selling weight loss drug (Orlistat, $900 million in sales in one year) and have improved the drug so side effects are dealt with. Just raised $2 million. Also negotiations to acquire private pharma with FDA approved women's health product. Very low share count and next to nothing market cap.

    Tremendous potential !

    http://m-pharma.ca/
     
  2. Million$man

    Million$man New Member

    Joined:
    Jul 26, 2016
    Messages:
    23
    Likes Received:
    0
  3. Million$man

    Million$man New Member

    Joined:
    Jul 26, 2016
    Messages:
    23
    Likes Received:
    0
    FDA Confirmed Faster Pathway to Market Approval for C-103
    M Pharmaceutical Inc. pursuing 505 (b) (2) pathway for C-103: M Pharma's reformulated version of Orlistat (C-103) is designed to maintain the safety and efficacy benefits of Orlistat while minimizing / eliminating the uncomfortable and embarrassing side effects. As part of the transaction, M Pharma has acquired issued US patents covering C-103 technology until 2030 from Chelatexx. The FDA confirmed C-103 is eligible for 505 (b) (2) in the US, which is significant because the 505 (b) (2) regulatory pathway should allow M Pharma to rely in part on Orlistat data, which could speed time to market.

    M Pharma estimates peak sales potential for C-103 of $200 million + annually.
     

Share This Page